Menu
Recruiting NCT07722013

Intermittent Ephedrine Boluses for Prophylaxis Against Postinduction Hypotension

No phase Interventional Postinduction Hypotension

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Normal Saline, Ephedrine.
Who it may be relevant to
Registry conditions: Postinduction Hypotension. Basic parameters: from 50 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Intermittent Ephedrine Boluses for Prophylaxis Against Postinduction Hypotension in High-risk Patients Undergoing Major Abdominal Surgery: a Randomized Double-blinded Controlled Trial: a Randomized Double-blinded Controlled Trial

Overview

The aim of this work is to assess the efficacy of intermittent ephedrine boluses in prophylaxis against postinduction hypotension in high-risk patients undergoing major abdominal surgery, compared to standard care.

Detailed description

Fluid responders (≥20% rise in perfusion index on passive leg raising) will receive 500-mL Ringer's boluses (up to 1500 mL). Anesthesia will be induced with fentanyl/propofol, intubated after neuromuscular blockade, and maintained with isoflurane (1.2% end-tidal). Study drug will be given at induction and every 5 minutes for 20 minutes, withheld if MAP ≥80 mmHg or a recent vasopressor dose. Hypotension (MAP \<65 mmHg) will be treated with 0.1 mg/kg ephedrine boluses (max 9 mg single). Post-incision care follows anesthetist discretion.

Interventions

  • Drug Normal Saline
    four 10-mL syringes of normal saline, The patient will receive the first dose of the intervention with induction (0.1 ml/kg). After induction of anesthesia, the study drug will be given every 5 min for 20 min and will be withheld if MAP was ≥80 mmHg or if any vasopressor is given within 2 min of the current scheduled dose
  • Drug Ephedrine
    four 10-mL syringes of ephedrine 1 mg/mL. The patient will receive the first dose of the intervention with induction (0.1 ml/kg). After induction of anesthesia, the study drug will be given every 5 min for 20 min and will be withheld if MAP was ≥80 mmHg or if any vasopressor is given within 2 min of the current scheduled dose.

Primary outcome measures

  • incidence of postinduction hypotension [Time frame: from induction of anesthesia until 20 minutes after induction]
Secondary outcome measures (1)
  • area under mean arterial pressure of 65 mmHg [Time frame: from induction of anesthesia until 20 minutes after induction]

Eligibility criteria

Inclusion criteria

  • Adult patients aged >50 years,
  • weight >50 kg,
  • American Society of Anesthesiologists (ASA) Physical Status score of > I,
  • undergoing major abdominal surgery

Exclusion criteria

  • Severe cardiac morbidities (impaired contractility with ejection fraction < 40%, heart block, significant uncontrolled arrhythmias, tight stenotic valvular lesions)
  • Acute cardiovascular pathologies: acute/decompensated heart failure, acute coronary syndrome
  • Uncontrolled hypertension (systolic blood pressure>150 mmHg)
  • Preoperative HR more than 110 bpm despite proper fluid management and patients with renal impairment
  • Renal impairment
  • Patients on vasopressor infusion,
  • Allergy of any of the study drugs

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Prevention

Study locations

Egypt · 1 center
  • Kasr Alainy Hospital — Cairo

Identifiers

NCT: NCT07722013 · MD-160-2026

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗